A Phase 1/2, Open Label, Dose Escalation Study to Determine Safety and Immunogenicity of Two (Prophylactic) COVID 19 DNA Vaccine Candidates (VB10.2129 [C1], a RBD Candidate and VB10.2210 [C2], a T Cell Candidate), in Healthy Adult Volunteers
Latest Information Update: 17 Apr 2024
At a glance
Most Recent Events
- 13 Aug 2023 Status changed from active, no longer recruiting to completed.
- 25 Oct 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Oct 2022.
- 25 Oct 2022 Status changed from recruiting to active, no longer recruiting.